Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Conditions: Advanced Solid Tumor; Metastatic Cancer; HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER-2 Protein Overexpression; Esophageal Cancer; Ovarian Cancer; Endometrium Cancer; Bladder Cancer; Pancreatic Cancer; Colorectal Cancer; Non Smal l Cell Lung Cancer; EGF-R Positive Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Triple Negative Breast Cancer; Cervical Cancer; Sarcoma Interventions: Biological: SNK01; Drug: Trastuzumab; Drug: Cetuximab Sponsor: NKMax America, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Erbitux | Gastroenterology | HER2 | Herceptin | Research | Sarcomas